SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

HC Wainwright Maintains LENZ Therapeutics at Buy, Cuts Target to $16

HC Wainwright lowered its price target from $38 to $16 while maintaining its Buy rating.

LENZ

Related stories